Published in J Virol on April 30, 2008
Cross-reacting antibodies enhance dengue virus infection in humans. Science (2010) 4.63
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol (2014) 2.34
Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology (2009) 2.26
Immature dengue virus: a veiled pathogen? PLoS Pathog (2010) 2.04
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92
The human antibody response to dengue virus infection. Viruses (2011) 1.79
Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One (2009) 1.72
An in-depth analysis of original antigenic sin in dengue virus infection. J Virol (2010) 1.63
Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol (2011) 1.51
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. Cell (2015) 1.51
Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology (2011) 1.48
Dengue viruses - an overview. Infect Ecol Epidemiol (2013) 1.40
A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One (2011) 1.36
Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A (2016) 1.31
Zika Virus: Medical Countermeasure Development Challenges. PLoS Negl Trop Dis (2016) 1.31
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe (2009) 1.27
Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity. J Virol (2012) 1.25
Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers. J Infect Dis (2010) 1.24
Dengue research opportunities in the Americas. J Infect Dis (2012) 1.22
Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis (2012) 1.22
Alternative complement pathway deregulation is correlated with dengue severity. PLoS One (2009) 1.20
Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog (2013) 1.20
Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol (2012) 1.17
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J (2011) 1.17
New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol (2015) 1.10
Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol (2012) 1.07
Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol (2009) 1.05
High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol (2013) 1.03
Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology (2012) 1.01
Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J Virol (2014) 1.00
Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. BMC Infect Dis (2012) 1.00
Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog (2014) 0.98
Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis (2013) 0.98
prM-antibody renders immature West Nile virus infectious in vivo. J Gen Virol (2011) 0.98
CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice. J Virol (2015) 0.97
Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog (2013) 0.97
Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J Virol (2010) 0.95
Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients. J Immunol (2012) 0.95
A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein. PLoS One (2012) 0.95
Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis (2014) 0.94
The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response. PLoS Negl Trop Dis (2015) 0.94
Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl Trop Dis (2012) 0.93
An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques. Am J Trop Med Hyg (2015) 0.93
Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J (2012) 0.92
PCP consensus sequences of flaviviruses: correlating variance with vector competence and disease phenotype. J Mol Biol (2009) 0.88
Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody. BMC Microbiol (2013) 0.87
Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol (2012) 0.87
Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency. Proc Natl Acad Sci U S A (2013) 0.86
Expression of dengue-3 premembrane and envelope polyprotein in lettuce chloroplasts. Plant Mol Biol (2011) 0.86
Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunology (2016) 0.86
Recombinant Envelope-Proteins with Mutations in the Conserved Fusion Loop Allow Specific Serological Diagnosis of Dengue-Infections. PLoS Negl Trop Dis (2015) 0.86
Dengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection. Front Immunol (2014) 0.85
Analysis of human monoclonal antibodies generated by dengue virus-specific memory B cells. Viral Immunol (2012) 0.84
The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis. ScientificWorldJournal (2013) 0.83
Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice. Sci Rep (2016) 0.81
Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus. Biologics (2013) 0.79
Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site. J Virol (2015) 0.79
The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol Mol Biol Rev (2017) 0.78
Aluminum hydroxide influences not only the extent but also the fine specificity and functional activity of antibody responses to tick-borne encephalitis virus in mice. J Virol (2013) 0.78
Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties. BMC Microbiol (2014) 0.78
Antibodies against immature virions are not a discriminating factor for dengue disease severity. PLoS Negl Trop Dis (2015) 0.77
Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine. PLoS One (2016) 0.77
Comprehensive mapping infection-enhancing epitopes of dengue pr protein using polyclonal antibody against prM. Appl Microbiol Biotechnol (2015) 0.77
Multi-walled carbon nanotubes increase antibody-producing B cells in mice immunized with a tetravalent vaccine candidate for dengue virus. J Nanobiotechnology (2016) 0.76
Clinical outcome and genetic differences within a monophyletic Dengue virus type 2 population. PLoS One (2015) 0.76
Immunization with Immune Complexes Modulates the Fine Specificity of Antibody Responses to a Flavivirus Antigen. J Virol (2015) 0.76
Nature and Extent of Genetic Diversity of Dengue Viruses Determined by 454 Pyrosequencing. PLoS One (2015) 0.76
Characterizing the Conformational Landscape of Flavivirus Fusion Peptides via Simulation and Experiment. Sci Rep (2016) 0.76
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
Total and Envelope Protein-Specific Antibody-Secreting Cell Response in Pediatric Dengue Is Highly Modulated by Age and Subsequent Infections. PLoS One (2016) 0.75
Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection. J Virol (2016) 0.75
Dengue patients exhibit higher levels of PrM and E antibodies than their asymptomatic counterparts. Biomed Res Int (2015) 0.75
MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus. F1000Res (2016) 0.75
Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein. PLoS One (2015) 0.75
Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection. Appl Microbiol Biotechnol (2015) 0.75
Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine. Open Forum Infect Dis (2015) 0.75
Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes. PLoS Negl Trop Dis (2015) 0.75
Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development. Front Microbiol (2017) 0.75
Dissecting the human serum antibody response to secondary dengue virus infections. PLoS Negl Trop Dis (2017) 0.75
Characterization and epitope mapping of Dengue virus type 1 specific monoclonal antibodies. Virol J (2017) 0.75
Identification of diagnostic peptide regions that distinguish Zika virus from related mosquito-borne Flaviviruses. PLoS One (2017) 0.75
Dengue and dengue hemorrhagic fever. Clin Microbiol Rev (1998) 19.59
Pathogenesis of dengue: challenges to molecular biology. Science (1988) 14.73
The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 12.25
Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol (2002) 10.92
Dengue: an update. Lancet Infect Dis (2002) 9.02
Research on dengue during World War II. Am J Trop Med Hyg (1952) 8.76
A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg (1988) 8.54
Structure of the dengue virus envelope protein after membrane fusion. Nature (2004) 7.97
A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A (2003) 7.76
Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol (1984) 5.62
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res (2003) 4.90
Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol (2001) 4.27
Antibody-enhanced dengue virus infection in primate leukocytes. Nature (1977) 4.18
Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg (1982) 4.04
Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology (1998) 3.80
Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol (1992) 3.79
Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol (2000) 3.70
Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis (2004) 3.68
Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg (1990) 3.41
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol (2002) 2.66
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol (2004) 2.64
Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J Virol (1989) 2.59
Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet (2002) 2.56
Comparison of capture immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assay (ELISA) and nonstructural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin Diagn Lab Immunol (2003) 2.46
Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol (1987) 2.39
Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis (1994) 2.37
Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol (2006) 2.33
Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol (1990) 2.05
Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis (2006) 1.99
The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol (2006) 1.93
Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation. Virology (1990) 1.91
Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol (2006) 1.91
Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol (1988) 1.83
Characterization of neutralizing antibodies to West Nile virus. Virology (2005) 1.81
Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica (2002) 1.75
Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg (1991) 1.54
Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg (2006) 1.45
Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol (2002) 1.40
Study of anti-dengue NS1 antibody by western blot. J Med Virol (1990) 1.36
Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis (2007) 1.33
Production of dimer-specific and dengue virus group cross-reactive mouse monoclonal antibodies to the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol (1991) 1.30
Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology (1991) 1.29
Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1. J Immunol (2005) 1.26
Human Dengue antibodies against structural and nonstructural proteins. Clin Diagn Lab Immunol (2000) 1.23
Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int J Infect Dis (2005) 1.17
Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses. J Gen Virol (1987) 1.15
Retrospective study of Western blot profiles in immune sera of natural dengue virus infections. J Med Virol (1999) 1.12
Identification of continuous epitopes of the envelope glycoprotein of dengue type 2 virus. Am J Trop Med Hyg (1989) 1.06
Characterization of retrovirus-based reporter viruses pseudotyped with the precursor membrane and envelope glycoproteins of four serotypes of dengue viruses. Virology (2007) 0.88
Incorporation of dengue virus replicon into virus-like particles by a cell line stably expressing precursor membrane and envelope proteins of dengue virus type 2. J Biomed Sci (2007) 0.87
Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines. Virus Genes (2007) 0.86
Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J Virol (2004) 0.80
Immunoreactivity and protective effects in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in a baculovirus expression system. J Gen Virol (1993) 0.80
Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics (2002) 2.94
Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia. Crit Care Med (2012) 2.68
Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health (2008) 2.09
Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis (2006) 1.99
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92
Enterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E. Cell Host Microbe (2011) 1.88
An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol (2004) 1.81
Laboratory diagnosis of dengue virus infection: current and future perspectives in clinical diagnosis and public health. J Microbiol Immunol Infect (2005) 1.81
Establishing a nationwide emergency department-based syndromic surveillance system for better public health responses in Taiwan. BMC Public Health (2008) 1.81
High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology (2003) 1.79
Detection of dengue virus replication in peripheral blood mononuclear cells from dengue virus type 2-infected patients by a reverse transcription-real-time PCR assay. J Clin Microbiol (2002) 1.71
Dengue type 3 virus in plasma is a population of closely related genomes: quasispecies. J Virol (2002) 1.69
The natural frequencies of the arterial system and their relation to the heart rate. IEEE Trans Biomed Eng (2004) 1.68
Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution. Proc Natl Acad Sci U S A (2004) 1.66
Estimating pathogen-specific asymptomatic ratios. Epidemiology (2010) 1.64
Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol (2006) 1.58
Incidence and case-fatality rates resulting from the 1998 enterovirus 71 outbreak in Taiwan. J Med Virol (2002) 1.57
Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan. Emerg Infect Dis (2003) 1.55
Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J Biol Chem (2010) 1.52
Study of sequence variation of dengue type 3 virus in naturally infected mosquitoes and human hosts: implications for transmission and evolution. J Virol (2004) 1.37
Human TLR3 recognizes dengue virus and modulates viral replication in vitro. Cell Microbiol (2009) 1.35
The role of imported cases and favorable meteorological conditions in the onset of dengue epidemics. PLoS Negl Trop Dis (2010) 1.34
1998 dengue hemorrhagic fever epidemic in Taiwan. Emerg Infect Dis (2004) 1.33
Temperature drops and the onset of severe avian influenza A H5N1 virus outbreaks. PLoS One (2007) 1.33
Intracellular localization and determination of a nuclear localization signal of the core protein of dengue virus. J Gen Virol (2002) 1.32
Laboratory-based surveillance and molecular epidemiology of influenza virus in Taiwan. J Clin Microbiol (2005) 1.26
Concurrent infections by two dengue virus serotypes among dengue patients in Taiwan. J Microbiol Immunol Infect (2003) 1.23
Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis (2012) 1.22
Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res (2007) 1.21
Effects of the El Niño-southern oscillation on dengue epidemics in Thailand, 1996-2005. BMC Public Health (2009) 1.17
Epidemiologic and clinical features of non-polio enteroviral infections in northern Taiwan in 2008. J Microbiol Immunol Infect (2011) 1.16
Clinical features of influenza A and B in children and association with myositis. J Microbiol Immunol Infect (2004) 1.16
Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther (2008) 1.16
A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res (2004) 1.16
Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem (2011) 1.16
A community-derived outbreak of adenovirus type 3 in children in Taiwan between 2004 and 2005. J Med Virol (2008) 1.15
Differences in replication capacity between enterovirus 71 isolates obtained from patients with encephalitis and those obtained from patients with herpangina in Taiwan. J Med Virol (2007) 1.14
Co-evolution positions and rules for antigenic variants of human influenza A/H3N2 viruses. BMC Bioinformatics (2009) 1.13
Spatial mapping of temporal risk characteristics to improve environmental health risk identification: a case study of a dengue epidemic in Taiwan. Sci Total Environ (2006) 1.13
Two clustering diffusion patterns identified from the 2001-2003 dengue epidemic, Kaohsiung, Taiwan. Am J Trop Med Hyg (2008) 1.13
Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis. Emerg Infect Dis (2004) 1.12
Seroprevalence of enterovirus 71 and no evidence of crossprotection of enterovirus 71 antibody against the other enteroviruses in kindergarten children in Taipei city. J Microbiol Immunol Infect (2011) 1.12
Taipei's use of a multi-channel mass risk communication program to rapidly reverse an epidemic of highly communicable disease. PLoS One (2009) 1.11
A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One (2009) 1.10
Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J Biol Chem (2012) 1.10
Pressure pulse velocity is related to the longitudinal elastic properties of the artery. Physiol Meas (2004) 1.10
Neutralizing antibody response and SARS severity. Emerg Infect Dis (2005) 1.08
From a basic principle of evolution to the heart rate of mammals. J Physiol (2015) 1.07
High levels of mecA DNA detected by a quantitative real-time PCR assay are associated with mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2009) 1.07
Strategically examining the full-genome of dengue virus type 3 in clinical isolates reveals its mutation spectra. Virol J (2005) 1.06
Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem (2009) 1.05
Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol (2006) 1.04
Lymphocyte activation and hepatic cellular infiltration in immunocompetent mice infected by dengue virus. J Med Virol (2004) 1.04
Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol (2007) 1.04
The classical Guyton view that mean systemic pressure, right atrial pressure, and venous resistance govern venous return is/is not correct. J Appl Physiol (1985) (2006) 1.04
High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol (2013) 1.03
Clinical manifestations of human coronavirus NL63 infection in children in Taiwan. Eur J Pediatr (2007) 1.03
Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome. Clin Infect Dis (2004) 1.02
DNA methylation and histone modification regulate silencing of OPG during tumor progression. J Cell Biochem (2009) 1.02
Surface marker epithelial cell adhesion molecule and E-cadherin facilitate the identification and selection of induced pluripotent stem cells. Stem Cell Rev (2011) 1.01
Coxsackieviruses infection in northern Taiwan--epidemiology and clinical characteristics. J Microbiol Immunol Infect (2009) 1.01
An outbreak of coxsackievirus A16 infection: comparison with other enteroviruses in a preschool in Taipei. J Microbiol Immunol Infect (2010) 1.00
The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum. J Virol (2010) 0.99
Emergence and evolution of avian H5N2 influenza viruses in chickens in Taiwan. J Virol (2014) 0.98
Epidemiology of respiratory syncytial virus infection in northern Taiwan, 2001-2005 -- seasonality, clinical characteristics, and disease burden. J Microbiol Immunol Infect (2007) 0.98
Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis (2013) 0.98
Japanese encephalitis virus genotype replacement, Taiwan, 2009-2010. Emerg Infect Dis (2011) 0.98
Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials (2011) 0.98
Epidemic pleurodynia caused by coxsackievirus B3 at a medical center in northern Taiwan. J Microbiol Immunol Infect (2010) 0.97
Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother (2008) 0.96
Antibody conjugated supported lipid bilayer for capturing and purification of viable tumor cells in blood for subsequent cell culture. Biomaterials (2013) 0.96
A strong endoplasmic reticulum retention signal in the stem-anchor region of envelope glycoprotein of dengue virus type 2 affects the production of virus-like particles. Virology (2008) 0.95
Emerged HA and NA mutants of the pandemic influenza H1N1 viruses with increasing epidemiological significance in Taipei and Kaohsiung, Taiwan, 2009-10. PLoS One (2012) 0.95
Spatial-temporal patterns of dengue in areas at risk of dengue hemorrhagic fever in Kaohsiung, Taiwan, 2002. Int J Infect Dis (2009) 0.94
MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. J Biomed Sci (2011) 0.94
Patient data, early SARS epidemic, Taiwan. Emerg Infect Dis (2004) 0.94
Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl Trop Dis (2012) 0.93
Microcirculatory characteristics of acupuncture points obtained by laser Doppler flowmetry. Physiol Meas (2007) 0.92